Newsfeeds - Spark Newswire

1 minute read

Cellectis Q4 EPS Adj EPS $(0.57) Beats $(0.71) Estimate, Sales $17.32M Beat $13.92M Estimate

Today, 6:47 AM

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.71) by 19.72 percent. This is a 18.75 percent decrease over losses of $(0.48) per share from the

CLLS

6 minute read

Earnings

Earnings Scheduled For March 8, 2023

By Benzinga Insights

Today, 6:47 AM

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

ABM

1 minute read

Earnings

A Preview Of Cellectis’s Earnings

By Benzinga Insights

Today, 6:47 AM

Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Wednesday, 2023-03-08. Here’s what investors need…

CLLS

4 minute read

Cellectis Announces Pricing Of Follow-On $20.2M Public Offering Of 8.8M American Depositary Shares At A Price Of $2.50/ADS; Plans To Use ~$17M Of Proceeds To Fund The Continued Clinical Development Of UCART 123, UCART22, UCART20x22, And UCARTCS1

By Happy Mohamed

Today, 6:47 AM

Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces

CLLS

2 minute read

5 Most Expensive Health Care Stocks You Should Worry About

By Lisa Levin

Today, 6:47 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

ATHE

4 minute read

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 6:47 AM

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

ACMR

4 minute read

Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket

By Lisa Levin

Today, 6:47 AM

Gainers

AEMD

1 minute read

Cellectis Touts Positive Preliminary Data From Two Leukemia Trials

By Vandana Singh

Today, 6:47 AM

Cellectis S.A (NASDAQ:CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01…

CLLS

1 minute read

Cellectis Announces Preliminary Clinical Data For UCART22 In ALL And UCART123 In AML

By Benzinga Newsdesk

Today, 6:47 AM

UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient

CLLS